Fennec Delays NDA Due to Manufacturing Facility Change
Insights - Fennec announced some bad news this morning. Their NDA submission for Pedmark has been pushed back by 9-12 months to “late 2019 to early 2020”. The NDA … Continue Reading
Read NowInsights
Aldeyra Shares Details On Phase 3 Pipeline Candidates
Insights - This morning, Aldeyra hosted their R&D day, where they discussed their pipeline and upcoming plans. Although no AC data was reported, the company did give color … Continue Reading
Read Now
The Street is Finally Starting to Pick Up on Bellus’ Story
Insights - It seems the market is starting to realize Bellus’ potential as the company touched a 52 week high today on the Canadian listing when it … Continue Reading
Read NowFennec’s $12.5M Loan Gives Company Viable Alternative To Commercialize Alone
Insights - Today Fennec (FENC) announced a $12.5 million senior loan with the Life Sciences Group at Bridge Bank. The loan will have a maturity date of October 1, … Continue Reading
Read NowAldeyra’s All Stock Deal Could Be Sign Of Validation
Insights - Today, Aldeyra (ALDX) acquired privately company Helio Vision for an all stock deal worth $12.5M, with milestones of up to additional $12.5M. The acquisition adds yet … Continue Reading
Read Now
Overlooked Name Could Be A Pillar To Cure of Multi-Billion Dollar Disease
Insights - SBPH is developing inarigivir, an immune activator that boosts the efficacy of the immune system fighting off Hepatitis B. Spring Bank’s candidate has the potential … Continue Reading
Member: Read NowAldeyra’s Enrollment Numbers Could Be Key Difference in Phase 3 Allergic Conjunctivitis
Insights - Aldeyra (ALDX) will be reporting results from their first Phase 3 study in allergic conjunctivitis (“AC”) sometime in early 2019 (we expect January). A positive … Continue Reading
Read Now